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We sought to investigate the magnitude of minor bleeding and identify risk factors for minor bleeds 
during non-vitamin K antagonist oral anticoagulant (NOAC) therapy.  
 
Methods 
This was an observational cohort study of patients with atrial fibrillation (AF) referred to a regional 
NOAC outpatient clinic between February 2013 and October 2017. The study population consisted of 
875 consecutive patients with AF who visited the NOAC outpatient unit to initiate treatment with 
apixaban (N=303), dabigatran (N=267) or rivaroxaban (N=305) for long-term ischemic stroke 
prophylaxis. Minor bleed was defined as every overt bleeding that does not fulfil the criteria of major 




Overall rate of minor bleeds was 19.2 per 100 patient years of follow up. Bleeding rates for apixaban, 
dabigatran and rivaroxaban were 26, 8.3 and 23 per 100 patient-years of follow-up. Next to the type 
of NOAC, the main risk indicators  for minor bleedings during NOAC therapy were a HAS-BLED score 
of 3 or higher and novel anticoagulant use (no history of vitamin K antagonist use). 
 
Limitation 




Our data showed that minor bleeds are common in novel NOAC users, especially when using 
apixaban and rivaroxaban. In the latter two NOACs, hematoma (bruises) and nose bleeds were more 
frequently observed and accounted for the difference with dabigatran. Besides type of NOAC, a 
higher HAS-BLED score and novel anticoagulant drug use were associated with an increased risk of 
minor bleeding. 
 














Non-vitamin K antagonist anticoagulation drugs (NOACs) entered the market in the US/EU beginning 
in 2009. Non-vitamin K oral anticoagulants such as apixaban, dabigatran, edoxaban, and rivaroxaban 
are direct selective inhibitors of activated coagulation factors X or II. NOACs have a good dose-
response relationship that eliminates the need to closely monitor coagulation levels. Several studies 
have confirmed the superior or similar efficacy and safety of NOACs over vitamin K antagonists (VKA) 
with respect to stroke and systemic embolic events (SEE), myocardial infarction, all-cause mortality 
and major-,intracranial- or gastrointestinal bleeding1,6,7,8,9.   
 
Given the increasing number of patients using  a NOAC, patients experience with this class of drugs in 
real life is very important 2. In a previous study we investigated the reasons why patients discontinue 
NOAC therapy. Next to lack of tolerability (side effects), the occurrence of minor bleeding was a 
major reason for the NOAC discontinuation.   
 
There is still not much known about minor bleeding in real life practice among atrial fibrillation 
patients. Firstly, NOACs are relatively novel and available knowledge mainly comes from large studies 
that focus on major bleeds, ischemic strokes and mortality. In this, evidence on the differences in 
patterns of minor bleeding  between NOACs is scarce, as well as potential risk indicators for minor 
bleeding. From Dresden NOAC registry we only know that more than 60 % of all rivaroxaban 
associated bleeding complications were found to be minor bleeding events3. Incidence rate of minor 
bleeding was 35.8 (95% Confidence Interval 32.2-39.7) per 100 patient years, clinically relevant non-
major bleeds 20.7 (CI 18.1-23.5) and for major bleeds 3.1 (CI 2.2-4.3) per 100 patient years.  This 10 
fold higher occurrence of minor bleeds has a major impact on patients quality of life. Given the 
lifelong indication of NOAC in atrial fibrillation almost every patient has a great chance of 
experiencing minor bleeds during his or her treatment.  
 
The central aim of this study was to investigate the “occurrence pattern” of minor bleeds (rates and 




In this study, all consecutive patients starting their NOAC therapy at the  cardiology outpatient clinic 
of the Medical Center Leeuwarden were included.  
 
All patients with indications for NOAC for AF were included in the study. Atrial fibrillation patients 
who previously were treated with VKA were also included. 
 
Exclusion criteria: 
- Patients with persistent AF who required temporary NOAC therapy for scheduled 
cardioversion or pulmonary vein isolation. 
-  Patients using NOAC for off label indication (like stroke prevention in prosthetic or 
mechanical heart valves) were excluded.    
- Atrial fibrillation patients who during the study switched to another NOAC 
 
The clinic features a well-structured and nurse-based NOAC unit that operates in cooperation with 
hospital thrombosis service, and operates in accordance with Dutch guidelines governing integrated 
anticoagulation services4. These guidelines describe how NOACs should be prescribed and 
administered. According to these guidelines, the prescribing cardiologist and thrombosis service 
nurse are responsible for informing patients of the risks and benefits of NOAC therapy, initiating 
NOAC therapy, therapy follow-up consultations, patient monitoring, and information transfers to 











At our NOAC clinic, thrombosis service nurses initiate NOAC treatment in patients with AF who were 
previously diagnosed by a referring cardiologist. Using a checklist, thrombosis service nurses review 
the treatment indications, prescribed dose, presence of comorbidities, patient’s renal function, and 
risk of thrombosis or bleeding as per CHA2DS2-VASc and HAS-BLED scores. They also provide the 
patients with relevant information about NOAC medications. Patients are routinely scheduled for 3, 
6, and 12 month follow-up appointments. At these appointments, the nurse will carefully monitor 
and document patients’ renal function and experiences such as side effects and minor bleeds with 
NOAC therapy. After the initial 12 months of NOAC therapy, patients are scheduled for once-yearly 
follow-ups.  
 
The patients are also encouraged to contact the clinic if they experience adverse  effects (including 
bleeding) or participate in planned interventions that might necessitate temporary NOAC 
discontinuation. Standardized question lists are used for adverse events at each clinic visit. These 
observations are subsequently documented in the patient’s electronic medical record. The dose and 
type of NOAC may be changed during follow-up visits due to deteriorations in renal function, age, 
bleeding risk, medication side effects, or the patient’s wishes after conferring with the referring 
cardiologist. Because of the clinic’s well-structured follow-up processes, high quality and detailed 
data on patients treated with NOACs is readily available.   
 
Study design 
This was an observational population based cohort study of patients with AF who were referred to a 
regional NOAC outpatient clinic between February 2013 to October 2017.  
 
All clinical data generated during the course of usual care were prospectively collected using the 
patients’ electronic medical records. This EMR system (EPD vision) collects and stores patient NOAC 
treatment data and records contacts with other health providers for NOAC-related problems, side 
effects, bleeding episodes, cardiovascular events, cerebrovascular events, medication changes or 
discontinuations, and deaths. Patients were followed up for a maximum of 3 years. 
 
Definitions of variables 
The primary outcome measure was time to first minor bleeding event..  Secondary objectives were 
the risks factors (age, sex, renal function, CHA2DS2-VASc and HAS-BLED scores, blood pressure, and 
prior VKA therapy) for, type and rates of minor bleeding. Minor bleed was defined as every overt 
bleeding that does not fulfil the criteria of major or non-major clinically relevant bleeding according 
to International Society on Thrombosis and Haemostasis (S. Kaatz et al )5.  
 
Ethics 
The Regional ethical committee reviewed the study protocol prior to the start of the study and 




Variables are presented as mean +/- standard deviation if normally distributed, or median and range 
if non-normally distributed. Categorical variables are presented using frequency counts and 
percentages.  
 
Between-group differences in baseline characteristics were tested using the Chi Square test for 
categorical variables and F-test (ANOVA) or Kruskal Wallis test for continuous variables, depending 
on the data distribution. The time to first bleeding was depicted graphically using the Kaplan-Meier 
approach. Associations between minor bleeding and type of NOAC, as well as potential confounders 
(CHADS-VASc, HAS-BLED, previous VKA use , age, sex, renal function, medical history of bleeding) 











included in the initial multivariable model. A backward elimination strategy was used to achieve the 
most suitable model to estimate the adjusted relative risks with the final multivariable model only 
including the risk factors associated with minor bleeding.  
 
To address the potential risk of informative censoring due to major bleeding or death, we performed 
three sensitivity analyses. 10 In this, the censored subjects were reclassified using three "worst case" 
scenario's: Scenario 1) The censored subjects with a major bleed were considered as experiencing a 
bleeding event  – still censoring at time of death. Scenario 2) The censored subjects with either a 
major bleed or death were considered as experiencing a bleeding event. Scenario 3) The patients 
with either a major bleed or death were considered as NOT having a minor bleed over maximum 
follow-up time of 36 months. 
 
By evaluating differences in risk estimates in the 3 scenario’s, the impact of informative censoring 
will be assessed. 
 
In cases where indication for NOAC was not longer present patients were censored (e.g. cancer, 
Watchman procedure). 
 
A 2-tailed P-value <0.05 was considered to indicate statistical significance. All analyses were 




The study population consisted of 875 consecutive patients with AF who visited the NOAC outpatient 
unit for initiation of treatment with apixaban (N=303), dabigatran (N=267) or rivaroxaban (N=305) for 
long-term ischemic stroke prophylaxis (Table 1). None of the participants used edoxaban. Median 
follow-up time was 15.7 months for the whole cohort (95% CI 14.9-16.6), 14.5 months (95% CI 13.8-
15.9) for apixaban, 15.0 months (95% CI 14.0-17.0) for dabigatran, and 18.2 months (95% CI 16.2-
23.7) for rivaroxaban. The median age was 70 years (range 39-98) and females accounted for 36% of 
the total study population. Most of the patients had received prior VKA therapy (52%) (N=455). Out 
of the 875 patients, 74 stopped due to an unplanned event that resulted in a lack of indication for 
NOAC treatment. Of these, 23 were administered apixaban, 31 were administered dabigatran, and 
20 were administered rivaroxaban.  
  
Freedom from minor bleeds 
Figure 1 presents the Kaplan-Meier estimate for freedom from minor bleeds, stratified by NOAC. 
Overall rate of minor bleeds was 19.2 (95% CI 16.6-22.2) per 100 patient years of follow up. Bleeding 
rates for apixaban, dabigatran and rivaroxaban were 26 (95% CI 20.5-32.6) , 8.3 (95% CI 5.4-12.2) and 
23 (95% CI 18.5-28.5) per 100 patient-years of follow-up. Our data show that apixaban and 
rivaroxaban were associated with more instances of minor bleeds, compared to dabigatran. 
Dabigatran had the fewest instances of minor bleeds over the whole follow-up period. The highest 
rate of minor bleeds for apixaban and rivaroxaban occurred during the first 3-12 months following 
NOAC initiation.  
 
Using multivariable Cox regression analysis, type of NOAC was independently associated with minor 
bleeding. In this, apixaban and rivaroxaban had an 2.7-fold and 2.8-fold increased risk for minor 
bleeding (adjusted HR=2.72 (95% CI 1.74 to 4.27; p < 0.001) and 2.79 (95% CI 1.79 to 4.32; p < 0.001), 
respectively) , as compared to dabigatran. 
 
As shown in Figure 2, we identified two other independent risk factors for minor bleeding , i.e. HAS-
BLED ≥3 (adjusted HR=1.46 (95% CI 0.98 to 2.17; p = 0.061)  and medical history of bleeding before 











As shown in the supplementary table,  no meaningful changes in risk estimates had occurred in 
either one of the sensitivity analyses. Only the HAS-BLED risk score showed a small increase in 
scenario 1 and 2. The risk estimates for type of NOAC were not affected, neither in univariate nor in 
the multivariable Cox regression analysis. 
 
Reported types of minor bleeds from NOAC`s 
Reported types of minor bleeds for each NOAC medication are listed in Table 2. There were 
significant differences in reported minor bleeds for the various NOAC medications. Our data showed 
that patients who received apixaban (25% (n=76 out of 303, p-value <0.001)) and rivaroxaban (28% 
(n=85 out of 305, p-value<0.001)) reported the most minor bleeds. Apixaban and rivaroxaban users 
experienced significantly more minor bleeds such as hematoma (defined as only bruises, no skin 
echymosis), nose and eye bleed. Cumulative minor bleed was higher in these two groups as well.  
 
Number of deaths  
As shown in Table 3, 22 patients (2.5%) had died during the 36 months follow-up. Of these patients, 
16 (1.8%) had not experienced a minor or major bleed prior to the time of death.  
 
DISCUSSION 
Our data detail the treatment durations and minor bleeds associated with three different NOAC 
medications (apixaban, dabigatran and rivaroxaban) following initiation and long-term follow-up 
within our NOAC clinical unit. This is one of the few long-term population-based follow-up studies to 
compare multiple NOAC medications administered through a NOAC specialty clinic. At this moment 
there is lack of data on this subject worldwide with which we can compare our results. 
 
Our clinical practice data showed significant difference in rate and type of minor bleeds between 
three NOAC medications. Potential risk factors for minor bleeds were type of NOAC, high HAS-BLED 
score and previous VKA use.   
 
Dabigatran had the lowest risk of minor bleeds where apixaban and rivaroxaban showed no 
significant difference. HAS-BLED score higher than 3 was associated with higher incidence of minor 
bleeds. This could be explained by a simple fact that higher HAS-BLED score corresponds with higher 
chance of bleeding.  History of previous VKA use also led to higher risk of minor bleeds. There is no 
exact explanation for this fact but we can speculate that patients  who previously used VKA are more 
critical or experienced when it comes to side effects or bleedings caused by anticoagulation therapy 
in general.  Another reason for previous VKA users having more minor bleeds could be that they 
switched to a NOAC because of bleeding on VKA, in the hope of less bleeding on NOAC. 
 
The highest rates of minor bleeds were measured within 3-12 months after initiation of therapy. 
Cumulative minor bleeds were most present in apixaban and rivaroxaban population. Hematoma 
(bruises), nose and retinal bleed were more present in apixaban and rivaroxaban population. This 
could be due to a same medication group (anti-Xa) effect. These type of minor bleeds together with 
gastro-intestinal minor bleeds are the most common among our population.  
Minor bleeding rates of rivaroxaban in Dresden study (35.8 per 100 patient years) are comparable 
with what we found in our population using rivaroxaban  (23 per 100 patient years).   
 
This study had several limitations. Our data were collected retrospectively and our cohort was non-
randomized. Minor bleeds were reported using standard adverse events questionnaires, 
administered by specialty nurses. There is a chance that patients don`t report all of the minor bleeds 
because some of them could be embarrassing or patient could feel uncomfortable to report it (such 
us vaginal or rectal bleeding). This can result in underreporting of minor bleeds. Furthermore, in 
evaluating minor bleeding, the occurrence of competing events could bias the risk estimates for 











for informative censoring. The risk estimated for type of NOAC were not affected, neither in 
univariate nor in the multivariable Cox regression analysis. In this, we feel that informative censoring, 
when even present, was very limited. 
 
HAS-BLED score was designed to predict major bleeding. Exploration of each component of HAS-
BLED score as it might be related specifically to minor bleeding should be part of any further 
research.  
 
One strength of this study was our relatively long duration period of 36 months compared to other 
studies. We also examined a large group of patients and obtained detailed follow-up records. We 
have prospectively collected data on patients who used VKA therapy prior to NOAC therapy and 
determined their reasons for switching. Further research should focus on management and costs of 
management of minor bleeds and on impact of minor bleeds on patient adherence.  
 
CONCLUSION 
Our data showed that minor bleeds are common in novel NOAC users, especially when using 
apixaban and rivaroxaban. In the latter two NOACs, hematoma (bruises) and nose bleeds were more 
frequently observed and accounted for the difference with dabigatran.  Besides type of NOAC, a 
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TABLES AND FIGURES 











Age 72 ± 9 69 ± 9 69 ± 9 70 ± 9 ˂0.001 
Male 184 (61%) 174 (65%) 201 (66%) 559 (64%) 0.36 









Systolic blood pressure  
Diastolic blood pressure 
142 ± 19 
84 ± 12 
143 ± 20 
85 ± 12 
140 ± 18 
83 ± 10 
142 ± 19 












124 (41 %) 
94 (31%) 
34 (11%) 










































































Reduced dose of NOAC* 57 (19%) 68 (26%) 42 (14%) 167 (19%) 0.002 
 
Categorical variables are presented as N (%), continuous variables are presented as mean ± SD or median (Q1-Q3), and 
analyzed with ANOVA or Kruskal-Wallis tests, as appropriate. The p-values (test for independence between NOAC 
medications and the respective baseline variable) tested the null hypothesis of no differences among the three types of 
NOAC medications. 




























































Hematoma (bruises) 37 (12%) 9 (3%) 36 (12%) 82 (9%) <0.001 
Nose  19 (6%) 5 (2%) 35 (11%) 59 (7%) <0.001 
Retinal 12 (4%) 2 (1%) 12 (4%) 26 (3%) 0.036 
Gastro-Intestinal  9 (3%) 6 (2%) 10 (3%) 25 (3%) 0.79 
Teeth Gum 3 (1%) 0 (0%) 2 (1%) 5 (0,6%) 0.33 
Vaginal 1 (0,3%) 2 (0,8%) 3 (1%) 6 (0,7%) 0.69 
Haemoptysis 1 (0,3%) 1 (0,4%) 0 (0%) 2 (0,2%) 0.55 
After Surgery 0 (0%) 0 (0%) 1 (0,3%) 1 (0,1%) 1.00 
Other 2 (0,7%) 1 (0,4%) 1 (0,3%) 4 (0,5%) 0.85 























Death 10 (3.3 %) 4 (1.5 %) 8 (2.6%) 22 (2.5%) 
















# No double counting within patients, first occurrence counted. (In apixaban there were 2 deaths after a minor 
bleed, in dabigatran there was 1 death after a major bleed, and in rivaroxaban there was 1 death after a major 




























Figure 2. Univariate and multivariable analysis of minor bleeding 
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